Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 50% status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA* NSCLC whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs)